| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/24/2023 | 5.76% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/04/2023 | 323.06% | HC Wainwright & Co. | $21 → $20 | Maintains | Buy |
| 11/14/2022 | 48.07% | Morgan Stanley | $11 → $7 | Maintains | Equal-Weight |
| 11/09/2022 | 323.06% | RBC Capital | $25 → $20 | Maintains | Outperform |
| 11/09/2022 | 48.07% | B of A Securities | $14 → $7 | Downgrades | Buy → Neutral |
| 09/21/2022 | 5.76% | JP Morgan | → $5 | Initiates Coverage On | → Overweight |
| 09/19/2022 | 344.21% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 09/09/2022 | 132.68% | Morgan Stanley | $17 → $11 | Downgrades | Overweight → Equal-Weight |
| 08/22/2022 | 323.06% | HC Wainwright & Co. | $44 → $20 | Maintains | Buy |
| 08/10/2022 | 513.43% | RBC Capital | $30 → $29 | Maintains | Outperform |
| 07/11/2022 | 830.72% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
| 05/10/2022 | 259.6% | Morgan Stanley | $30 → $17 | Maintains | Overweight |
| 05/10/2022 | 534.58% | RBC Capital | $34 → $30 | Maintains | Outperform |
| 04/12/2022 | 534.58% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 03/04/2022 | 1042.25% | HC Wainwright & Co. | $55 → $54 | Maintains | Buy |
| 02/01/2022 | 513.43% | Morgan Stanley | $47 → $29 | Maintains | Overweight |
| 11/09/2021 | 830.72% | Wolfe Research | → $44 | Initiates Coverage On | → Outperform |
| 11/03/2021 | 619.2% | RBC Capital | $33 → $34 | Maintains | Outperform |
| 09/07/2021 | 894.18% | Morgan Stanley | $51 → $47 | Maintains | Overweight |
| 08/09/2021 | 598.04% | RBC Capital | → $33 | Initiates Coverage On | → Outperform |
| 07/16/2021 | 978.79% | Morgan Stanley | $53 → $51 | Maintains | Overweight |
| 06/15/2021 | 873.03% | Cantor Fitzgerald | → $46 | Initiates Coverage On | → Overweight |
| 05/14/2021 | 1063.41% | HC Wainwright & Co. | $57 → $55 | Maintains | Buy |
| 05/10/2021 | 1021.1% | Morgan Stanley | $55 → $53 | Maintains | Overweight |
| 04/26/2021 | 1105.71% | HC Wainwright & Co. | $48 → $57 | Maintains | Buy |
| 03/23/2021 | 1063.41% | Morgan Stanley | $56 → $55 | Maintains | Overweight |
| 03/19/2021 | 915.34% | HC Wainwright & Co. | $47 → $48 | Maintains | Buy |
| 12/16/2020 | 1084.56% | Morgan Stanley | $52 → $56 | Maintains | Overweight |
| 12/03/2020 | 788.42% | Stifel | → $42 | Initiates Coverage On | → Hold |
| 10/29/2020 | 894.18% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 10/13/2020 | 999.95% | Morgan Stanley | $53 → $52 | Maintains | Overweight |
| 06/09/2020 | 1021.1% | Morgan Stanley | → $53 | Initiates Coverage On | → Overweight |
| 06/09/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
What is the target price for ADC Therapeutics (ADCT)?
There is no price target for ADC Therapeutics
What is the most recent analyst rating for ADC Therapeutics (ADCT)?
There is no analyst for ADC Therapeutics
When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?
There is no next analyst rating for ADC Therapeutics
Is the Analyst Rating ADC Therapeutics (ADCT) correct?
There is no next analyst rating for ADC Therapeutics